Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

Bruce Leuchter, CEO, Neurvati, discusses why patient engagement is essential to understanding rare diseases and driving the ...

In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts ...

In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains ...

The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how ...

As drug development increasingly targets multiple indications, pharma companies must make strategic branding ...

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical ...

In the third part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, describes ...

Dipanwita Das, CEO and co-founder of Sorcero, chats with Pharma Commerce to dig into the evolving drug development landscape, ...

In the second part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains ...

State Medicaid leaders create a plan to ensure safety, affordability, and equitable access for children and families living with rare diseases.